eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Original paper

Efficacy of gentamicin 0.3% solution of oral erosions healing in patients with severe generalized recessive dystrophic epidermolysis bullosa and its impact on the expression of type VII collagen

Katarzyna Osipowicz
1
,
Piotr Wychowanski
2
,
Pawel Nieckula
2
,
Sara Shamsa
3
,
Katarzyna Wertheim-Tysarowska
4
,
Katarzyna Wozniak
1
,
Cezary Kowalewski
1

1.
Department of Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland
2.
Department of Department of Oral Surgery, Medical University of Warsaw, Warsaw, Poland
3.
Department of Paediatric Dentistry, Medical University of Warsaw, Warsaw, Poland
4.
Department of Medical Genetics, Institute of Mother and Child, Warsaw, Poland
Adv Dermatol Allergol 2021; XXXVIII (6): 979–984
Online publish date: 2020/07/14
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Epidermolysis bullosa (EB) is a rare genetic skin disorder inherited either in autosomal recessive (AR) or autosomal dominant (AD) manner and characterized by blistering of the skin and mucous membranes. According to a subtype of EB, the oral manifes-tations and dental involvement vary in frequency and in severity. The most severe dental problems occur in patients with junction-al epidermolysis bullosa (JEB) and severe generalized dystrophic epidermolysis bullosa (RDEB) and involve enamel erosion and development of blisters followed by painful oral wounds. Oral mucosa lesions decrease patients’ quality of life and may contrib-ute to difficulties in nutrition leading to cachexia.

Aim
Assessment of efficacy of gentamicin 0.3% solution in the healing and preventing of oral erosions in patients with RDEB and evaluating its impact on the expression of type VII collagen.

Material and methods
The study included four female patients with RDEB, aged 16–42 who show different mutations in the COL7A1 gene and were administered the mouth rinse two times daily with a solution of 0.3% gentamycin for 4 consecutive weeks. Prior to and at the end of the study, the samples from oral mucosa were collected to estimate the expression of type VII collagen by immunofluorescence test.

Results
The clinical improvement of oral wounds healing and reduced number of new blisters and mucous membrane soreness as well as partial re-expression of type VII collagen was observed in all studied patients.

Conclusions
Topical gentamicin therapy of oral cavity in RDEB patients resulted in clinical improvement of mucosal lesions and re-expression of collagen type VII.

keywords:

gentamycin 03% solution, VII collagen, oral mucosa, junctional epidermolysis bullosa, recessive dystrophic epidermolysis bull-osa

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.